Tryptic cleavage of proteinase-activated receptor-2 (PAR 2 ) causes the unmasking of a tethered receptor-activating sequence, S 37 LIGRLDTP. . . . We sought to determine, in the amino-terminal sequence of the PAR 2 tethered ligand, the key amino acid residues that are responsible for receptor activation. Using site-directed mutagenesis, nine PAR 2 mutants with alanine substitutions in the first six amino acids of the tethered ligand, . These mutants, together with wild-type PAR 2 (PAR 2 wt), were expressed in Kirsten virustransformed rat kidney cells and were then assessed for receptor-mediated calcium signaling upon activation by trypsin and by receptor-activating peptides like SLIGRL-NH 2 . In addition, the release of the N-terminal receptor sequence that is cleaved from PAR 2 by trypsin activation was monitored in the above cell lines using a site-targeted anti-receptor antibody. All PAR 2 constructs were activated by SL-NH 2 , and all mutated tethered ligand sequences were unmasked by trypsin. However, differential activation of the receptor by trypsin in these mutants was observed: PAR 2 mutants PAR 2 A 37-38 and PAR 2 L 37 S 38 , in which the first two amino-terminal tethered ligand residues (S 37 L 38 ) are either changed to alanines or reversed, yielded little or no response to trypsin, nor did PAR 2 A 37,39 -42 . However, trypsin activated all other constructs. We conclude that the aminoterminal tethered ligand dipeptide sequence S 37 L 38 plays a major role in the activation of PAR 2 .
by receptor-activating peptides like SLIGRL-NH 2 . In addition, the release of the N-terminal receptor sequence that is cleaved from PAR 2 by trypsin activation was monitored in the above cell lines using a site-targeted anti-receptor antibody. All PAR 2 constructs were activated by SL-NH 2 , and all mutated tethered ligand sequences were unmasked by trypsin. However, differential activation of the receptor by trypsin in these mutants was observed: PAR 2 mutants PAR 2 A 37-38 and PAR 2 L 37 S 38 , in which the first two amino-terminal tethered ligand residues (S 37 L 38 ) are either changed to alanines or reversed, yielded little or no response to trypsin, nor did PAR 2 A 37,39 -42 . However, trypsin activated all other constructs. We conclude that the aminoterminal tethered ligand dipeptide sequence S 37 L 38 plays a major role in the activation of PAR 2 .
Activation of rat proteinase-activated receptor-2 (PAR 2 ) by trypsin, like PAR 1 activation by thrombin (Vu et al., 1991) , involves the proteolytic unmasking of an amino-terminal receptor sequence (S 37 LIGRLDTP. . . ) that acts as a receptoractivating tethered ligand (Vu et al., 1991; Nystedt et al., 1994) . As with PAR 1 , PAR 2 can be activated by short peptides (e.g., S 1 LIGRL 6 -NH 2 ) based on the tethered ligand sequence. These receptor-activating peptides (PAR 2 APs) can mimic the activation of PAR 2 by trypsin in tissues and PAR 2 -expressing cells (Nystedt et al., 1994; Al-Ani et al., 1995; Böhm et al., 1996; Hollenberg et al., 1997; Déry et al., 1998; Hollenberg and Compton, 2002) . Although the structure-activity relationships (SARs) for PAR 2 activation by synthetic peptides based on the S 1 LIGRL 6 -NH 2 motif have been studied in some depth Kawabata et al., 1999; Maryanoff et al., 2001) , there has yet to be a systematic SAR study to determine the key residues in the PAR 2 revealed tethered ligand sequence that cause receptor activation. For the peptides, leucine at position 2 is essential for receptor activation, and the isoleucine at position 3 and the arginine at position 5 both contribute to peptide potency. Importantly, simply reversing the first two amino acids (L 1 SIGRL 6 -NH 2 ) leads to a complete loss of activity, as does acylation of the amino terminus (N-acyl-S 1 LIGRL 6 -NH 2 ). In contrast, the relative importance of these same residues in the proteolytically revealed tethered ligand has not yet been established. Furthermore, data obtained by us for PAR 2 (Al-Ani et al., 1999a , 2002b and by others for PAR 1 (Blackhart et al., 2000) suggest that the soluble peptide agonists and the correspond-ing tethered ligand sequences seem to interact differently with the body of the receptor. Based on the apparent discrepancies between our previous SAR work with the synthetic PAR 2 APs and our preliminary findings with the receptor mutants with changes both in extracellular loop-2 and in the tethered ligand of PAR 2 (Al-Ani et al., 2002b) , we decided to explore further the SAR profile for the tethered ligand sequence itself.
We hypothesized that 1) the amino-terminal amino acids (S 37 L 38 ) would be crucial for receptor activation and that 2) Ile 39 and Arg 41 would also contribute to receptor activation by the tethered ligand. To test these hypotheses, all of the first six amino acids at the amino terminus of the tethered ligand were replaced with alanines (Table 1 ). The wild-type receptor and the alanine-replacement receptor mutants were expressed in Kirsten-virus-transformed rat kidney (KNRK) cells (Al-Ani et al., 1999a) , along with PAR 2 L 37 S 38 , having a reversal of the first two tethered ligand residues (S 37 L 38 3 L 37 S 38 ). A calcium signaling assay (Al-Ani et al., 1999a; Kawabata et al., 1999) was used to assess activation of the wild-type and mutated receptors both by trypsin and by the PAR 2 AP S 1 LIGRL 6 -NH 2 . In addition, the calcium signaling assay was used to monitor, in wild-type PAR 2 (PAR 2 wt) and in the mutant receptors, the activity of synthetic peptides having the same sequences as those of the mutated tetheredligand sequences (e.g., A 1 LIGRL 6 -NH 2 , corresponding to A 37 LIGRL 42 . . . ). Added to the functional evaluation of the expressed receptor mutants, the efficiency of receptor cleavage by trypsin to unmask the tethered ligand was monitored for all PAR 2 variants using an antibody (SLAW-A) that recognizes the sequence released at the R 36 /S 37 cleavage/activation site. A loss of reactivity with SLAW-A (immunocytochemistry) confirms the release of the N-terminal receptor sequence that masks the tethered ligand (Compton et al., 2001; Al-Ani et al., 2002a) . Our data point to the key role played by the first two amino acids of the tethered ligand (S 37 L 38 ), in contrast with other residues within the first six amino acids that play lesser roles.
Materials and Methods
Peptides and Other Reagents. All peptides were synthesized as carboxamides by solid-phase methods at the peptide synthesis facility [Dr. Denis McMaster, University of Calgary, Faculty of Medicine (Calgary, AB, Canada)]. High-performance liquid chromatography analysis, mass spectral analysis, and quantitative amino acid analysis confirmed the composition and purity of all peptides. Stock solutions, prepared in 25 mM HEPES buffer, pH 7.4, were standardized by quantitative amino acid analysis to verify peptide concentration. Porcine trypsin (14,900 units/mg) was obtained from Sigma (St. Louis, MO). A maximum specific activity of 20,000 units/mg was used to calculate the approximate molar concentration of trypsin in the incubation medium (1 unit/ml Х 2 nM).
Preparation of PAR 2 Constructs and their Expression in KNRK cells. As previously documented Al-Ani et al., 1999a,b) , rat PAR 2 was cloned from kidney cDNA using the primer pairs: forward primer (containing a HindIII site and Kozak sequence shown in bold), 5Ј-TCAAGCTTCCACCATGC-GAAGTCTCAGCCTGGC-3Ј; reverse primer (containing SmaI site shown in bold), 5Ј-CCCGGGCTCAGTAGGAGGTTTTAACAC-3Ј. Then, the rat PAR 2 cDNA, for which sequence verification was done (Sanger et al., 1977;  DNA services facility at the University of Calgary) was subcloned further into the pcDNA3 mammalian expression vector (Invitrogen, Carlsbad, CA), which was used to prepare all 10 receptor mutants shown in Table 1 . The receptor mutants described in Table 1 . The wild-type and PAR 2 mutants in pcDNA3 were then transfected into KNRK cells (American Type Culture Collection, Manassas, VA), as described previously (Al-Ani et al., 1999a,b) to yield permanent cell lines for further study. Transfected cells (either vector alone or PAR 2 -containing vectors) were subcloned in G-418-containing medium (0.6 mg/ml), and PAR 2 -expressing cells were isolated by fluorescence-activated cell sorting (FACS) with the use of the anti-receptor SLAW-A antibody as described elsewhere for a B5 anti-PAR 2 antibody used by us previously (Kong et al., 1997; Al-Ani et al., 1999a,b) . The SLAW-A antiserum recognizes the PAR 2 receptor sequence that is released upon proteolytic activation of the receptor ( -GGYGGC) (receptor antigenic sequences represented in bold; GGYGGC added for radiolabeling and cysteine-coupling). In the cell lines so isolated, Ͼ80% of the populations (flow cytometry) were found to exhibit reactivity with the SLAW-A antibody with an equivalent fluorescence intensity on a percell basis, in keeping with our previous work (Al-Ani et al., 1999a , 2002b . Cells were routinely propagated as described previously (Al-Ani et al., 1999a) in G-418 (0.6 mg/ml)-containing growth medium and were subcultured by re-suspension in calcium-free isotonic saline/EDTA solution, without the use of trypsin.
Evaluating the Cleavage of PAR 2 Variants by Trypsin. PAR 2 variant cell lines were grown to about 85% confluence. These clones possess an N-terminal sequence that is proximal to the receptor's cleavage/activation sequence and therefore potentially released from the cell upon cleavage of PAR 2 by trypsin at site Arg 36 . The rabbit 
polyclonal antiserum (SLAW-A) mentioned above was employed to monitor the disappearance of the signal (generated by the receptor sequence up to and including residue Arg 36 ) upon trypsin treatment of all expressed mutants, thereby confirming trypsin cleavage (Compton et al., 2001; Al-Ani et al., 2002a) . In brief, KNRK cells expressing the receptor constructs were exposed to 20 units/ml trypsin (40 nM) for 5 min at room temperature, and proteolysis was terminated by the addition of 1 g/ml soya trypsin inhibitor. Cells were then harvested by a cytospin procedure in preparation for immunocytochemical detection of receptor with SLAW-A, comparing the receptor staining observed in cells both before and after trypsin treatment with reference to the disappearance of the SLAW-A immunoreactivity observed in control wild-type PAR 2 -expressing KNRK cells. To quantify the disappearance of SLAW-A-reactive epitope by trypsin treatment, as monitored by immunocytochemistry, a morphometric analysis was used as described previously (Compton et al., 2001; Al-Ani and Hollenberg, 2003) . In brief, several microscopic fields, comprising 200 or more fixed stained cells, were surveyed at random, and cells were scored as either SLAW-positive or SLAW-negative. The ratio of positive to negative cells in the untreated or trypsin-treated cells was then calculated. Upon trypsin treatment, a loss of over 80% of SLAW-A reactivity was routinely observed in all previous control experiments with wild-type PAR 2 KNRK cells. The values obtained using the immunocytochemical approach agreed with data obtained using FACS analysis to document the removal of the SLAW-A epitope by trypsin (Compton et al., 2001; Al-Ani and Hollenberg, 2003) .
Calcium Signaling Assay. Measurements of trypsin and peptide-stimulated fluorescence emission (reflecting an increase in intracellular calcium from a baseline of about 30 nM to a peak of about 340 nM) were done with cells grown to about 85% confluence and disaggregated with calcium-free isotonic phosphate-buffered saline containing 0.2 mM EDTA. PAR 2 -transfected KNRK cells were loaded with the intracellular calcium indicator Fluo-3 (Molecular Probes Inc., Eugene, OR) at a final concentration of 22 M (25 g/ml) of fluo-3 acetoxymethyl ester Minta et al., 1989) , as described previously (Al-Ani et al., 1999a; Kawabata et al., 1999) . Fluorescence measurements, reflecting elevations of intracellular calcium, were conducted at 24°C using an AMINCO-Bowman series 2 luminescence spectrometer (Spectronic Unicam, Rochester, NY), with an excitation wavelength of 480 nm and an emission recorded at 530 nm. The fluorescence signals caused by the addition of test agonists (trypsin or peptides, added to 2 ml of a cell suspension of about 3 ϫ 10 5 cells/ml) were expressed as described previously (AlAni et al., 1999a; Kawabata et al., 1999; Compton et al., 2000) , relative to the fluorescence peak height yielded by replicate cell suspensions treated with 2 M concentrations of the ionophore A23187 (Sigma Chemical). Measurements were done using three or more replicate cell suspensions derived from two or more independently grown groups of cells. To express quantitatively the sensitivity of the PAR 2 tethered ligand mutants for trypsin activation, relative to the sensitivity of wild-type PAR 2 , a ratio was calculated (R EC,T ) based on the concentration of trypsin required to cause a given calcium signal in the wild-type receptor (EC WT ) relative to the concentration of trypsin required to cause the equivalent calcium signal in the mutant PAR 2 receptor with an altered tethered ligand sequence (EC MUTANT ). Thus, for trypsin activation, R EC,T ϭ EC WT / EC MUTANT . Values of this ratio Ͻ1 denote a receptor that requires a higher concentration of trypsin to cause the same cellular response as for PAR 2 wt and is therefore less sensitive than the wild-type receptor. Similarly, as we have done previously , we expressed the sensitivity of the receptors to the synthetic peptide analogs also as a ratio (R EC,P ) of the concentration of the wild-type peptide, SLIGRL-NH 2 , required for a given calcium signal (EC SLIGRL-NH2 ), relative to the concentration of test peptide (EC PEP -TIDE) required to generate the equivalent calcium response. Data for the wild-type receptor, denoted in the text by open symbols for peptide concentration-effect curves, are shown in Fig. 4 ; the peptide sensitivities of the mutant receptors are denoted by closed symbols in Fig. 4 . The EC values were obtained along the linear portions of the concentration-response curves, like those shown in Figs. 2 and 4. Four to six points along the concentration-response curves were used to calculate the averages for the R EC,T and R EC,P values. Measurements done in this manner yielded average values, for which the standard error of the mean was less than 10% of the magnitude of the average.
Results

Expression and Responsiveness of PAR 2 Variants.
All receptor variants (Table 1) were expressed in KNRK cells as permanent cell lines, maintained in the presence of G-418. FACS analysis and immunocytochemical detection of the receptor using the SLAW-A antibody revealed that all mutant cell lines expressed a receptor density equivalent to that of the wild-type cell line, KNRK-PAR 2 wt. Not only did all cell lines exhibit equivalent average cell surface fluorescence and immunoreactivity (FACS) but Ն80% of all cells in each line were found to express the receptor by immunocytochemical morphometric analysis (data not shown). More importantly, the responsiveness (calcium signaling) of all PAR 2 variant cell lines to the PAR 2 AP SLIGRL-NH 2 was equivalent, with comparable EC 50 values (3 to 10 M) and maximal calcium signals at 50 M SLIGRL-NH 2 that were 80% or greater than the signal generated by PAR 2 wt ( Fig. 1 and data not shown for constructs designated by ✖ and ✚ in Table 1 ).
Sensitivity of the PAR 2 Variants to Trypsin. Given that the different cell lines expressed an equivalent cell surface abundance of functional receptor determined by FACS analysis and responsiveness to SLIGRL-NH 2, the next step was to measure their sensitivity to trypsin, reflecting the Fig. 1 . Concentration-effect curves for SLIGRL-NH 2 -stimulated calcium signaling in wild-type and mutated PAR 2 -expressing KNRK cell lines. Permanent KNRK cell lines expressing the wild-type and mutated PAR 2 constructs with altered tethered ligand sequences (Table 1) were evaluated for their sensitivity to SLIGRL-NH 2 (calcium signaling) as outlined under Materials and Methods. The fluorescence emission (E 530 ) in response to increasing concentrations of SLIGRL-NH 2 was expressed as a percentage (% A23187) of the signal generated with 2 M of the ionophore, A23187. Cell lines are represented by these symbols (Table 1) activity of the revealed tethered ligand (Fig. 2) . Most striking was the complete lack of activity of trypsin in PAR 2 L 37 S 38 , which was otherwise fully responsive to SLIGRL-NH 2 (Fig. 2  and Table 2 , ᭜), and the essential lack of trypsin sensitivity of the construct with A 37 A 38 substitutions (PAR 2 A 37-38 , ‹; Fig. 2 ). In contrast, changing only the first amino acid to alanine (PAR 2 S 37 A, f; Fig. 2 ) resulted in a receptor with sensitivity toward trypsin that was the same as that of the wild-type receptor (PAR 2 wt, F; Fig. 2 ). In contrast, changing Leu 38 to alanine at the second position of the tethered ligand (PAR 2 L 38 A: OE, Fig. 2 ) caused a ϳ10-fold reduction in the sensitivity to trypsin but nonetheless resulted in a receptor that could still respond to trypsin with a maximal calcium response of ϳ75% of that observed for PAR 2 wt. In addition to the crucial importance of the first two amino acids for tethered ligand activity, further alanine substitutions revealed the importance of residues Ile 39 and Arg 41 (PAR 2 I 39 A and PAR 2 R 41 A, and ✚; Fig. 2 ). Overall, the relative potencies of trypsin, reflecting the relative activities of the sequences as tethered ligands unmasked by proteolysis, were ( Fig. 2 (Fig. 2) . Quantitatively, the sensitivities of all receptor variants toward trypsin, relative to PAR 2 wt (R EC,T values), are summarized in Table 2 , expressed as a ratio (R EC,T ) of the concentrations of trypsin required to cause a calcium response in the wild-type receptor (EC WT ) relative to the concentration of trypsin required to generate the equivalent calcium signal in the receptor mutant (EC MUTANT ). Thus, R EC,T ϭ EC WT /EC MUTANT , where values Ͻ1.0 denote a receptor mutant with reduced sensitivity to trypsin.
Unmasking of Receptor Variants by Trypsin. Although all receptor variants expressed comparable amounts of functional cell surface receptors (responses to SLIGRL-NH 2 and FACS), it was essential for interpreting the trypsin sensitivity data (Fig. 2) to know that all variants were similarly cleaved by trypsin at Arg 36 to reveal the tethered ligand sequence. To assess the unmasking of the tethered ligand sequence in all variants, cells were first exposed to trypsin for 5 min at a trypsin concentration (40 nM; 20 units/ml) sufficient to expose the tethered ligand and generate a maximum calcium signal in PAR 2 wt. Cleavage was monitored as outlined under Materials and Methods, with the SLAW-A antibody that detects only the receptor sequence removed by trypsin. As shown in Fig. 3 , trypsin was able efficiently to remove the epitope detected by SLAW-A from the wild-type receptor that is fully activated by trypsin, as well as from receptor variants that showed either reduced sensitivity (PAR 2 A 39-42 ) or no activity (PAR 2 L 37 S 38 ) upon trypsin activation. A similar removal of the epitope visualized by the SLAW-A antibody was also observed for all mutant PAR 2 cell lines (not shown). Morphometric analysis of the fixed stained cells revealed that, as for PAR 2 wt, brief trypsin treatment eliminated SLAW-A reactivity from 80% or more of all of the mutant receptor-bearing cells. Comparable results were obtained using FACS analysis of the trypsin-treated cells (not shown). Thus, trypsin treatment caused an equivalent cleavage and exposure of the tethered ligand in all receptor mutants.
Activity of Tethered Ligand Sequences as Soluble Peptides. Although in previous work, we and others had obtained structure-activity data for alanine substitutions in the receptor-selective PAR 2 -activating peptide sequence, S 1 LIGRL 6 -NH 2 Maryanoff et al., 2001) , it was necessary in the present study to evaluate again the activity of the synthetic peptides corresponding to the mutated tethered ligand sequences not only in PAR 2 wt but also in the receptor mutants possessing the corresponding tethered ligand sequence with the 'alanine walk' mutations. Thus, as outlined in Table 1 and Fig. 4 , nine synthetic peptides, SLIGRL-NH 2 (wild-type sequence), ALIGRL-NH 2 , SAIGRL-NH 2 , SLAGRL-NH 2 , SLIARL-NH 2 , SLIGAL-NH 2 , AAIGRL-NH 2 , SLAAAA-NH 2 , and LSIGRL-NH 2 were tested for activity (calcium signal) in both PAR 2 wt and in most of the receptor mutants having the cognate tethered ligand sequence. Because neither AAIGRL-NH 2 nor SLAAAA-NH 2 was found to be active in the calcium signaling assay (below), the peptides ALAAAA-NH 2 and AAAAAA-NH 2 were presumed to be inactive and were not tested in the interests of economy. As shown in Fig. 4 , at concentrations in the range of 200 to 400 M, the peptides SAIGRL-NH 2 (OE, ‚), AAIGRL-NH 2 (‹, ), SLAAAA-NH 2 (Š, ), and LSIGRL-NH 2 (᭜, ᭛) were completely inactive both in PAR 2 wt and in the receptor mutants possessing the same sequence as the mutated tethered ligand. In contrast, the other peptide analogs displayed relative potencies that clustered in three groups, with EC 50 values in the ranges of 3, 35, and 120 M, as summarized in the next paragraph.
The relative order of potencies of the peptides for activating the receptor (Fig. 4 and Table 2 ) was: SLIGRL-NH 2 Ϸ SLIARL-NH 2 Ͼ Ͼ ALIGRL-NH 2 Ͼ Ͼ SLAGRL-NH 2 Ϸ SLI-GAL-NH 2 , in contrast with the inactive peptides, SAIGRL-NH 2 , AAIGRL-NH 2 , SLAAAA-NH 2, and LSIGRL-NH 2 . The relative potencies of these different sequences for activating PAR 2 in relation to the activity of SLIGRL-NH 2 were expressed quantitatively, as we have done previously (Hollenberg et al., 1997), as a ratio (R EC,P ) of the concentration Fig. 2 . Trypsin sensitivity of wild-type and mutated PAR 2 -KNRK cell lines. Concentration-response measurements were done for trypsin-stimulated calcium signaling using the wild-type and mutated PAR 2 -expressing KNRK cell lines with altered tethered ligand sequences (Table 1) , as outlined in the legend of Fig. 1 of SLIGRL-NH 2 required to cause a given calcium signal EC SLIGRL-NH2 , relative to the concentration of the peptide analog EC PEPTIDE required to generate the equivalent calcium response in either the wild-type receptor (PAR 2 wt) or in the corresponding receptor mutant (i.e., R EC,P ϭ EC S -LIGR-NH2 / EC PEPTIDE : Table 2 ).
Discussion
Our study is the first to examine systematically the structure-activity relationships for the activation of PAR 2 by its tethered ligand sequence. The main finding of our study was that the first two amino acids of the tethered ligand of rat PAR 2 , in tandem, play a key role in receptor activation. This conclusion was supported by the data indicating that the revealed tethered ligand SLAAAA. . . was able to generate a substantial calcium signal in response to trypsin, whereas the receptor mutants with revealed tethered ligands AAIGRL. . . , ALAAAA. . . , and LSIGRL. . . generated little or no calcium signal in response to trypsin. Thus, the SL. . . motif on its own as a tethered ligand was sufficient to generate a substantial receptor signal. This activity for the tethered ligand would not have been predicted because the soluble PAR 2 AP SLAAAA-NH 2 did not activate PAR 2 wt.
To interpret the sensitivity to trypsin (calcium signal) as reflecting the activity of the tethered ligand, it was important to establish two key criteria: 1) that the receptor mutants were expressing an equivalent abundance of functional cell surface receptor and 2) that the tethered ligand in all of the receptor variants was unmasked by trypsin with comparable efficiency. Our data indicate that equivalent densities of functional receptor were indeed expressed in all cell lines (FACS analysis and comparable sensitivities to the PAR 2 -activating peptide, SLIGRL-NH 2 ). Furthermore, the immunocytochemical analysis of trypsin-treated receptor-expressing cells revealed an equivalent removal of the sequence N-terminal to Arg 36 that is visualized by SLAW-A. We had already identified the R 36 S 37 site as the principle target for trypsin cleavage in the expressed receptor, resulting in the removal of the N-terminal epitope visualized by the SLAW-A antibody (Al-Ani and Hollenberg, 2003) . Thus, both of the principal criteria required to interpret the trypsin sensitivity data were met, and the simple presence or absence of signaling generated by trypsin can be taken clearly to reflect the activity or lack thereof of a given tethered ligand sequence. That said, interpreting the relative activities of trypsin as reflecting the relative activities of the revealed tethered ligands in those receptor mutants that did yield calcium signals requires a further assumption that must be taken into account.
The assumption that must be made to use the R EC,T values to reflect the relative activities of the tethered ligand mutants is that the rate of trypsin cleavage must be the same for all receptor mutants and that this rate must not be limiting for generating a calcium signal. We were able with the immunocytochemical/morphometric approach to determine successfully that the extent of trypsin cleavage was the same for all mutants, within the time frame of signaling (5 min); unfortunately, however, we could not accurately measure the precise rate constants for cleavage for each construct because of the technical limitations of our measurements of SLAW-A epitope removal. That said, the finding of equivalent cleavage of all PAR 2 variants within 5 min strongly supports the assumption that the cleavage rates were comparable. Moreover, the clustering of the R EC,T values for 1) PAR 2 wt, PAR 2 S 37 A, and PAR 2 G 40 A, and 2) PAR 2 I 39 A, PAR 2 R 41 A, and PAR 2 A 39 -42 ( Fig. 2 and Table 2 ) with mutations either at or downstream of the trypsin cleavage/activation site supports the hypothesis that the trypsin cleavage rate is not a factor in interpreting the data.
Given that the two key criteria for interpreting the relative trypsin sensitivities were essentially met, we used the R EC,T values (Table 2) to reflect the relative activities of the revealed tethered ligands. There were major discrepancies between the SARs for activation of the receptor by the tethered ligand sequences (Fig. 2 and Table 2 ) as opposed to the SARs for the soluble PAR-APs (Fig. 4 and Table 2 ). For instance, the sequences S 37 LAAAA and S 37 AIGRL. . . were quite active as tethered ligands (Š, OE; Fig. 2 ), whereas the peptides S 1 LAAAA 6 -NH 2 and S 1 AIGRL 6 -NH 2 were devoid of activity (Š, , OE, ‚; Fig. 4) . Furthermore, the tethered ligand sequence, A 37 LIGRL. . . , was as active as the wild-type sequence, whereas the activity of the peptide, A 1 LIGRL 6 -NH 2 , was considerably reduced (about 10-fold) compared with SLI- The relative activity values for activation by trypsin (R EC,T ) or for activation by the synthetic peptides (R EC,P ) as carboxamides corresponding to the cognate tethered ligands were calculated from the data shown in Figs. 2 and 4 , according to the formulae: R EC,T ϭ EC WT /EC MUTANT and R EC,P ϭ EC SLIGRL-NH2 /EC PEPTIDE , as outlined under Materials and Methods . Thus, the value for the wild-type sequence is unity, whereas values Ͻ1 denote a tethered ligand or peptide with an activity less than that of the wild-type sequence. Alanine and other substitutions in the tethered ligand sequence are shown in bold type. The symbols denote the sequences of the cognate PAR-APs used to activate either the wild-type (open symbols) or mutant receptor (closed symbols) as shown in Fig. 4 . The closed symbols are also used for the trypsin activation data (Fig. 2) (Fig. 4 and Table 2 ). Thus, in keeping with previous results obtained by us and by others (Blackhart et al., 2000; Al-Ani et al., 2002b) , our new data point out more emphatically that the SAR data obtained for activation of the proteinase-activated receptors only by the synthetic peptides cannot be used as a basis for understanding the tethered ligand mechanism. In our previous study (Al-Ani et al., 2002b) , we focused primarily on potential interactions between the fifth residue of the revealed tethered ligand (Arg 41 ) and acidic residues in extracellular loop-2. Our data provided evidence against such an interaction but did not at all establish the key tethered ligand residues essential for receptor activation. Clearly, simply reversing the first two residues of the revealed tethered ligand (PAR 2 L 37 S 38 ) or replacing the first two residues with alanine (PAR 2 A 37-38 ), leaving the other tethered ligand residues unchanged, substantially reduced or completely abrogated the ability of the revealed tethered ligand to activate the receptor (Fig. 2, ᭜ and ‹) . However, with all other amino acids except the Ser 37 and Leu 38 residues changed to alanines (PAR 2 A 39 -42 ), the revealed tethered ligand (S 37 LAAAA. . . ) was still able to cause a substantial activation of the receptor (Fig. 2, Š) . The interaction of the S 37 L 38 motif with the body of the receptor would therefore seem to be both sufficient and necessary to activate the receptor. Nonetheless, substituting alanine for serine at the N termi- nus of the revealed tethered ligand (PAR 2 S 37 A) led to a sequence with an activation profile equivalent to that of the wild-type tethered ligand (compare F and f in Fig. 2 ). Other amino acids that can substitute for the S 37 L 38 motif of the revealed tethered ligand to yield full receptor activation remain to be determined. In this regard, substitution of the Leu 38 with alanine (PAR 2 L 38 A, OE; Fig. 2 ) led to a considerable loss of activity of the tethered ligand. Based on our data, one can suggest that hydrophobic residues at positions 2 and 3 of the tethered ligand may interact in a complementary pocket of the remainder of the receptor to trigger signaling.
In contrast with the discrepancies already mentioned, the SAR data for the tethered ligand sequences do parallel, to some degree, the SAR profile for the PAR 2 -activating peptides Maryanoff et al., 2001 ). For instance, neither the peptide LSIGRL-NH 2 nor the tethered ligand sequence L 37 SIGRL. . . was able to cause receptor activation. Furthermore, the previous SAR data for the synthetic peptides pointing to the importance of the isoleucine at the third position and the arginine at the fifth position Maryanoff et al., 2001) (Fig. 2, J) , albeit with a substantially lower activity than that of the sequence, S 37 LAAAA. . . (Fig. 2, Š) . It seems that although there are specific steric requirements for an efficient activation of the receptor (the S 37 L 38 motif), there may also be 'negative' constraints built into the tethered ligand that can be removed by the homogeneous replacement of all six tethered ligand residues by alanine.
Taken together, our data highlight the primary importance of the first two tethered ligand amino acids, SL, as critical for receptor activation. This conclusion could not have been reached based on the SAR data obtained with the soluble PAR 2 Aps alone. Furthermore, our study indicates the contributions (albeit secondary) of the third and fifth (Ile 39 and Arg 41 ) residues for tethered ligand activity. Thus, for the design of potential PAR 2 antagonists, the pharmacophores of the SL motif would seem to be paramount, in concert with the Leu 39 and Arg 41 side chains. That said, the activity of PAR 2 A [37] [38] [39] [40] [41] [42] with alanine replacements at all six tethered ligand residues should sound a cautionary note, suggesting that the proteolytic exposure of the tethered ligand may remove a prior structural constraint that enables the SL motif, to trigger signaling efficiently. It will be of considerable interest in future work to determine whether the first two amino acids of the PAR 1 tethered ligand are similarly critical for receptor activation. Table 1 were exposed to increasing concentrations of the synthetic peptides (as carboxamides) representing either the wild-type tethered ligand sequence, SLIGRL-NH 2 (E) or the sequences of the corresponding mutated tethered ligands. Increases in intracellular calcium were monitored, as outlined in the legend to Fig. 1 , as a percentage (%A23187) of the fluorescence emission (E 530 ) caused by 2 M concentrations of the ionophore A23187. Peptides corresponding to the altered tethered ligand sequence were tested either in PAR 2 wt (open symbols) or in the cognate receptor with the corresponding tethered ligand sequence (closed symbols). The synthetic peptides evaluated were: E, SLIGRL-NH 2 ; ✖, v, SLIARL-NH 2 ; f, Ⅺ, ALIGRL-NH 2 ; ✚, ¹, SLIGAL-NH 2 ; ƒ, SLAGRL-NH 2 ; OE, ‚, SAIGRL-NH 2 ; ‹, , AAIGRL-NH 2 ; Š, , SLAAAA-NH 2 ; and ᭜, ᭛, LSI-GRL-NH 2 . Values represent the averages Ϯ S.E.M. (bars) of measurements made with three or more separately grown cell samples. For symbols without error bars, the magnitude of the bars fell within the size of the symbol. 
